Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
P83111
UPID:
LACTB_HUMAN
Alternative names:
-
Alternative UPACC:
P83111; P83096
Background:
Serine beta-lactamase-like protein LACTB, located in the mitochondria, plays a pivotal role in regulating mitochondrial lipid metabolism. It achieves this by modulating the protein levels of PISD, a key enzyme in the conversion of phosphatidylserine to phosphatidylethanolamine, thus influencing mitochondrial lipid composition and function.
Therapeutic significance:
Understanding the role of Serine beta-lactamase-like protein LACTB could open doors to potential therapeutic strategies. Its function as a tumor suppressor, particularly in inhibiting the proliferation of various breast cancer cells, underscores its potential in cancer therapy by targeting mitochondrial lipid metabolism.